Sökning: WFRF:(Hermanson Monica) >
TP53 mutations and ...
TP53 mutations and MDM2(SNP309) identify subgroups of AML patients with impaired outcome
-
- Jakobsen Falk, Ingrid (författare)
- Linköpings universitet,Avdelningen för läkemedelsforskning,Hälsouniversitetet
-
- Willander, Kerstin (författare)
- Linköpings universitet,Avdelningen för cellbiologi,Hälsouniversitetet,Region Östergötland, Hematologiska kliniken US
-
- Chaireti, Roza (författare)
- Linköpings universitet,Avdelningen för mikrobiologi och molekylär medicin,Hälsouniversitetet,Region Östergötland, Medicinska akutkliniken,Karolinska University Hospital, Sweden
-
visa fler...
-
- Lund, Johan (författare)
- Karolinska Institutet,Huddinge University Hospital, Sweden
-
- Nahi, Hareth (författare)
- Karolinska Institutet,Huddinge University Hospital, Sweden
-
- Hermanson, Monica (författare)
- Uppsala universitet,Medicinsk genetik och genomik,Uppsala University, Sweden
-
- Green, Henrik (författare)
- National Board Forens Med, Department Forens Genet and Forens Toxicol, Linkoping, Sweden
-
- Lotfi, Kourosh (författare)
- Linköpings universitet,Avdelningen för läkemedelsforskning,Hälsouniversitetet,Region Östergötland, Hematologiska kliniken US
-
- Söderkvist, Peter (författare)
- Linköpings universitet,Avdelningen för cellbiologi,Hälsouniversitetet,Region Östergötland, Klinisk patologi och klinisk genetik
-
visa färre...
-
(creator_code:org_t)
- 2014-10-01
- 2015
- Engelska.
-
Ingår i: European Journal of Haematology. - : Wiley. - 0902-4441 .- 1600-0609. ; 94:4, s. 355-362
- Relaterad länk:
-
http://liu.diva-port...
-
visa fler...
-
https://liu.diva-por... (primary) (Raw object)
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
http://kipublication...
-
https://urn.kb.se/re...
-
visa färre...
Abstract
Ämnesord
Stäng
- BackgroundTP53 is commonly mutated in several cancers and confers treatment resistance and poor prognosis. Altered expression of mouse double minute 2 (MDM2), a negative regulator of p53, may also attenuate normal p53 signaling, thereby enhancing tumor transformation and resistance to apoptosis. The single nucleotide polymorphism (SNP) 309 has been reported to increase MDM2 expression and impair normal p53 response. Experimental designWe investigated the frequency and impact of TP53 mutations (TP53mut) and MDM2(SNP309) on treatment outcome and overall survival (OS) in 189 Swedish acute myeloid leukemia patients. The genetic analyses were performed using SSCA and direct sequencing (for mutations in exon 5-8 of TP53) and Pyrosequencing (for the MDM2(SNP309)). ResultsWe found a high frequency (22%) of TP53mut in patients with cytogenetic aberrations, with association to high-risk cytogenetics (P<0.001). TP53mut patients had lower response rates (22% compared with 76% CR in TP53 wild-type (wt) patients, P<0.001) and reduced OS (2 and 16months, respectively, P<0.001). In TP53wt patients with high or intermediate risk cytogenetic aberrations, the MDM2(SNP309) conferred an impaired outcome, with patients carrying the alternative G-allele having shorter OS compared with T/T patients (median 9 vs. 50months, P=0.020). ConclusionsOur results show that TP53mut analysis and MDM2(SNP309) genotyping may be useful tools for prognostication, risk stratification, and selection of patients most likely to benefit from new drugs targeting the p53 signaling pathway.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Hematologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Hematology (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine (hsv//eng)
Nyckelord
- acute myeloid leukemia
- TP53
- MDM2
- SNP309
- prognostic markers
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas